Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
biotech
10
×
boston blog main
boston top stories
10
×
deals
10
×
life sciences
national blog main
national top stories
startups
new york blog main
new york top stories
san francisco blog main
clinical trials
fda
investing
san francisco top stories
boston
cancer immunotherapy
glaxosmithkline
ipo
national
novartis
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
alnylam pharmaceuticals
boulder/denver blog main
boulder/denver top stories
cancer
cell therapy
crispr
detroit blog main
detroit top stories
eli lilly
fulcrum therapeutics
gene therapy
generic drugs
immunotherapy
indiana blog main
indiana top stories
What
new
10
×
medicines
biotech
drug
therapeutics
address
adds
bio
called
companies
company
deal
developing
disease
drugs
earlier
ipo
life
million
raised
research
roundup
science
startup
absorb
acquire
ago
agreed
aiming
aims
alliance
allosteric
ambys
approach
approval
areas
arrival
bails
based
big
Language
unset
Current search:
biotech
×
deals
×
" boston top stories "
×
new
×
@xconomy.com
3 years ago
Two Days, Six IPOs, and $1B Raised for Biotech Research & More
@xconomy.com
4 years ago
CereVasc Lands $44M for New Medical Device to Drain “Water on the Brain”
@xconomy.com
4 years ago
HotSpot Therapeutics Adds $65M to Steer Allosteric Medicines to the Clinic
@xconomy.com
4 years ago
Lyra Therapeutics IPO Raises $56M for Tests of Tech for Runny Noses
@xconomy.com
4 years ago
Novartis to Acquire MedCo and FDA-Ready Cholesterol Drug for $9.7B
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Flagship’s Omega Aims to Take Epigenetic Drugs a Step Further
@xconomy.com
5 years ago
Bio Roundup: Biogen’s Strategy, Drug Price Convo, NASH News & More
@xconomy.com
5 years ago
Brii Bio’s Alliance with VBI Vaccines Adds Hepatitis B Drug to Pipeline
@xconomy.com
5 years ago
With Big Takeda Deal at Launch, Can Ambys Keep Control of Its Future?